VolitionRx Limited Schedules Second Quarter 2024 Earnings Conference Call and Business Update
Rhea-AI Summary
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Thursday, August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2024 and provide a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, and Dr. Andrew Retter. Participants can join via phone or listen to a live audio webcast on Volition's investor relations website. A replay of the call will be available until August 29, 2024. This event provides an opportunity for investors and analysts to gain insights into Volition's recent performance and future outlook.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VNRX gained 0.51%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call to take place on Thursday August 15 at 8:30 a.m.
Event: VolitionRx Limited Second Quarter 2024 Earnings and Business Update Conference Call
Date: Thursday, August 15, 2024
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13747711
Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer and Dr. Andrew Retter, Chief Medical Officer. The call will provide an update on important events that have taken place in the second quarter of 2024 and upcoming milestones.
A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at https://ir.volition.com. In addition, a telephone replay of the call will be available until August 29, 2024. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-schedules-second-quarter-2024-earnings-conference-call-and-business-update-302215437.html
SOURCE VolitionRx Limited
FAQ
When is VolitionRx (VNRX) hosting its Q2 2024 earnings call?
How can investors join VolitionRx's (VNRX) Q2 2024 earnings conference call?
Until what date will the replay of VolitionRx's (VNRX) Q2 2024 earnings call be available?
Who will be hosting VolitionRx's (VNRX) Q2 2024 earnings conference call?
